0.6470 USD
+0.0152
2.41%
At close Dec 5, 4:00 PM EST
1 day
2.41%
5 days
1.09%
1 month
-15.97%
3 months
-46.08%
6 months
-84.52%
Year to date
-76.73%
1 year
-77.14%
5 years
-99.19%
10 years
-99.33%
 

About: BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

Employees: 71

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

36% more funds holding

Funds holding: 11 [Q2] → 15 (+4) [Q3]

18% more capital invested

Capital invested by funds: $7.81M [Q2] → $9.24M (+$1.42M) [Q3]

17.29% more ownership

Funds ownership: 33.3% [Q2] → 50.59% (+17.29%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 7

Research analyst outlook

We haven’t received any recent analyst ratings for PHGE.

Financial journalist opinion

Based on 3 articles about PHGE published over the past 30 days

Neutral
Seeking Alpha
3 weeks ago
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Sara Nik – H.C. Wainwright Operator Greetings, and welcome to the BiomX Third Quarter 2024 Financial Results Conference Call.
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 weeks ago
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
Neutral
GlobeNewsWire
3 weeks ago
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
Neutral
GlobeNewsWire
1 month ago
BiomX Announces a Mandatory Unit Separation
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.
BiomX Announces a Mandatory Unit Separation
Positive
Zacks Investment Research
2 months ago
BiomX Stock Gains From Favorable Study Data Presentation on BX004
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept.
BiomX Stock Gains From Favorable Study Data Presentation on BX004
Neutral
GlobeNewsWire
2 months ago
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections.
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
Neutral
GlobeNewsWire
3 months ago
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Neutral
GlobeNewsWire
3 months ago
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
Neutral
Seeking Alpha
3 months ago
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE ) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & Company Farhana Sakloth - Ladenburg Thalmann Operator Greetings, and welcome to BiomX Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
Charts implemented using Lightweight Charts™